Status:
COMPLETED
Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Children
Lead Sponsor:
Dr. Soetomo General Hospital
Conditions:
Pediatric Pulmonary Hypertension
Eligibility:
All Genders
1-17 years
Phase:
PHASE4
Brief Summary
To analyze the efficacy of beraprost and sildenafil for treatment of pulmonary hypertension in children with left to right shunt. analyze the efficacy and side effects.
Detailed Description
Eligibility criteria: Inclusion: 1. children aged 1-17 years with left to right shunt, diagnosed as pulmonary hypertension. 2. free from chronic pulmonary disease 3. never performed any cardiac surg...
Eligibility Criteria
Inclusion
- diagnosed as pulmonary hypertension with left to right shunt CHD (VSD, ASD, PDA and combination)
- agree to enroll in this study
Exclusion
- suffer from chronic lung disease
- suffer from soft tissue tumor, HIV/AIDS
- under interferon therapy
- already performed any cardiac surgery
- already got anti-PH remedy
Key Trial Info
Start Date :
April 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 30 2017
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03431649
Start Date
April 1 2017
End Date
October 30 2017
Last Update
February 13 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. Soetomo General Hospital
Surabaya, East Java, Indonesia